Clearside BiomedicalCLSD
CLSD
About: Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Employees: 30
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
203% more call options, than puts
Call options by funds: $194K | Put options by funds: $64K
0% more funds holding
Funds holding: 49 [Q2] → 49 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
5.17% less ownership
Funds ownership: 18.62% [Q2] → 13.45% (-5.17%) [Q3]
30% less capital invested
Capital invested by funds: $18.1M [Q2] → $12.8M (-$5.34M) [Q3]
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
588%
upside
Avg. target
$6
588%
upside
High target
$6
588%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Daniil Gataulin 25% 1-year accuracy 8 / 32 met price target | 588%upside $6 | Buy Maintained | 15 Nov 2024 |
HC Wainwright & Co. Yi Chen 39% 1-year accuracy 60 / 154 met price target | 588%upside $6 | Buy Reiterated | 14 Nov 2024 |
Needham Serge Belanger 40% 1-year accuracy 50 / 126 met price target | 588%upside $6 | Buy Reiterated | 13 Nov 2024 |
Financial journalist opinion
Based on 3 articles about CLSD published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye
ALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the official journal of The Royal College of Ophthalmologists, Eye, published a summary of critical insights into drug development and regulatory processes based on a presentation at the prestigious annual Edridge Green Lecture by Clearside's Chief Medical Officer and Executive Vice President, Head of Research and Development, Dr. Victor Chong.
Positive
Zacks Investment Research
1 week ago
Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now
Clearside Biomedical (CLSD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Neutral
GlobeNewsWire
3 weeks ago
Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States
- Commercial, Clinical and Regulatory Expertise Establish Clearside as the Leader in Suprachoroidal Delivery - - Multiple Events at Asia-Pacific Vitreo-Retina Society Congress Highlighting Clearside's Pipeline Programs and Suprachoroidal Delivery Technology - - Oral Presentations Delivered on ODYSSEY Wet AMD Topline Results – ALPHARETTA, Ga., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that presentations highlighting Clearside's suprachoroidal delivery technology and data on its pipeline programs were delivered in medical meetings in Asia, Europe and the United States.
Positive
Zacks Investment Research
1 month ago
All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy
Clearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Seeking Alpha
1 month ago
Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Victor Chong - Chief Medical Officer Charlie Deignan - CFO Conference Call Participants Annabel Samimy - Stifel Andreas Argyrides - Oppenheimer Debanjana Chatterjee - JonesTrading Operator Greetings, and welcome to the Clearside Biomedical Third Quarter 2024 Financial Results and Corporate Update Call. At this time, all participants are in a listen-only mode.
Negative
Zacks Investment Research
1 month ago
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.15 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside's Suprachoroidal Space (SCS ® ) Delivery Platform - ALPHARETTA, Ga., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the Company's Asia-Pacific partner, Arctic Vision, has signed a new commercial collaboration agreement with Santen Pharmaceutical Co., Ltd.
Neutral
GlobeNewsWire
1 month ago
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
ALPHARETTA, Ga., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer and EVP, Head of Research & Development, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024 at 8:00 a.m. ET in New York, NY.
Neutral
GlobeNewsWire
1 month ago
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors
ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Tony Gibney as Chair of its Board of Directors, effective November 1, 2024. Mr. Gibney, who joined Clearside's Board as an independent director in April 2024, succeeds Clay Thorp, who will continue serving as a member of the Board.
Neutral
GlobeNewsWire
1 month ago
Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024
ALPHARETTA, Ga., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2024 financial results will be reported on Tuesday, November 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Charts implemented using Lightweight Charts™